Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
RAPP
Stock Latest News
The Fly
Rapport Therapeutics price target raised to $65 from $53 at BTIG
6d ago
RAPP
Premium
Ratings
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
8d ago
RAPP
Premium
The Fly
Rapport Therapeutics assumed with a Buy at Truist
8d ago
RAPP
Premium
Ratings
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
19d ago
RAPP
Premium
Company Announcements
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
19d ago
RAPP
Premium
The Fly
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
19d ago
RAPP
Premium
Company Announcements
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
1M ago
8K
RAPP
Premium
The Fly
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
1M ago
RAPP
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Premium
The Fly
Closing Bell Movers: Markets on edge ahead of US-Iran talks
2M ago
FGI
SLP
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
2M ago
RAPP
Premium
Ratings
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
3M ago
RAPP
Premium
The Fly
Rapport Therapeutics files automatic mixed securities shelf
3M ago
RAPP
Premium
The Fly
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
3M ago
RAPP
Premium
The Fly
Rapport Therapeutics sees cash runway into 2H29
3M ago
RAPP
Premium
The Fly
Rapport, Tenacia announce collaboration for RAP-219 in Greater China
3M ago
RAPP
Premium
Company Announcements
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
4M ago
RAPP
Premium
The Fly
Rapport Therapeutics initiated with an Overweight at Wells Fargo
4M ago
RAPP
Premium
Ratings
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating
5M ago
RAPP
Premium
Ratings
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating
5M ago
RAPP
Premium
Ratings
Buy Rating on RAP-219 Underscored by Differentiated Clinical Profile, Conservative Phase 3 Design, and Favorable Risk–Reward
5M ago
RAPP
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
